Physician profile
Eric M Ashkin
NPI 1457385205
$1,278.86
in general payments reported to CMS, 2019-2025
23 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $14.83 · 2021: $246 · 2022: $304 · 2023: $167 · 2024: $202 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $172.42 | 2019-2023 | Lo Loestrin Fe |
| Aspira Women'S Health INC | $129.42 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.82 | 2019-2024 | |
| Hologic Sales and Service, LLC | $97.35 | 2019-2023 | Aptima, Thinprep 2000 Processor |
| Pfizer INC. | $94.63 | 2021-2023 | |
| Medtronic, INC. | $94.50 | 2024 | Sonicision |
| Astellas Pharma US INC | $77.92 | 2024-2025 | Veozah |
| Allergan, INC. | $69.97 | 2019 | |
| Meditrina | $62.01 | 2024-2025 | |
| Myovant Sciences INC. | $55.40 | 2021 | |
| Avion Pharmaceuticals | $44.69 | 2019-2020 | |
| Daiichi Sankyo INC. | $42.96 | 2022-2023 | Injectafer |
| Therapeuticsmd, INC. | $42.68 | 2019-2022 | |
| Coopersurgical, INC. | $35.37 | 2023 | Mara Console, Summit Doppler |
| Vertical Pharmaceuticals, LLC | $34.51 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $24.10 | 2024 | Prolia, Evenity |
| Sumitomo Pharma America, INC. | $21.37 | 2024 | Gemtesa |
| Cumberland Pharmaceuticals, INC. | $19.46 | 2025 | Kristalose |
| Exeltis, USA INC. | $18.42 | 2022 | |
| Mylan Pharmaceuticals INC. | $14.29 | 2022 | |
| Mayne Pharma Commercial LLC | $13.93 | 2022 | |
| Sanofi Pasteur INC. | $11.64 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Ashkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.